TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.
TAK-220 is a CCR5 antagonist, part of the new class of anti-human immunodeficiency virus type 1 (anti-HIV-1) entry inhibitors. We evaluated the anti-HIV-1 interactions between TAK-220 and various antiretrovirals in vitro. Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted.
Tremblay
Cécile L
CL
Massachusetts General Hospital, 65 Landsdowne St., Room 419, Cambridge, MA 02139, USA. mshirsch@partners.org
Giguel
Françoise
F
Guan
Yongbiao
Y
Chou
Ting-Chao
TC
Takashima
Katsunori
K
Hirsch
Martin S
MS
D019380:Anti-HIV Agents / Q000494:pharmacology*; D065100:CCR5 Receptor Antagonists; D004357:Drug Synergism; D015658:HIV Infections / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D018894:Reverse Transcriptase Inhibitors